Contents

Clinical Outcomes—Paroxysmal .......................................................................................................................... 2
  2-Year Follow-Up ........................................................................................................................................... 2
  < 2 Year Follow-Up .................................................................................................................................... 2
  Redos ......................................................................................................................................................... 3

Clinical Outcomes—Persistent .......................................................................................................................... 3
  ≤ 2 Year Follow-Up ................................................................................................................................... 3
  Acute Outcomes ......................................................................................................................................... 4

Reviews and Meta-Analyses .............................................................................................................................. 4

Safety Focus .................................................................................................................................................... 5
  ACE ........................................................................................................................................................... 5
  Anticoagulation ........................................................................................................................................ 6
  Esophageal Injury ...................................................................................................................................... 6
  Inflammation and Coagulation .................................................................................................................. 6
  Overall Complications ............................................................................................................................. 6
  Phrenic Nerve Injury ................................................................................................................................. 7
  PV Stenosis .............................................................................................................................................. 7

Other Considerations ........................................................................................................................................ 7
  Predictors of Success ................................................................................................................................. 7
  Linear Ablation ....................................................................................................................................... 7
  Imaging ..................................................................................................................................................... 8
  Signal Quality .......................................................................................................................................... 8
  Voltage Mapping .................................................................................................................................... 8

Pre-Clinical and Technical ................................................................................................................................ 8

Case Studies .................................................................................................................................................. 8

Guidelines and Consensus Statements .......................................................................................................... 9

This bibliography includes a complete listing of peer-reviewed, published data using the Phased RF technology. Search Terms Used in PubMed: Phased RF, Duty Cycled RF, Duty-Cycled RF; Circular Multi-Electrode Ablation Catheter; Pulmonary Vein Catheter Ablation Catheter (PVAC); Multi-Electrode Ablation; Multielectrode Ablation Catheter; Multiarray Ablation Catheter (MAAC); Multi-Array Ablation Catheter (MAAC) and Multipolar Pulmonary Isolation. English language articles only.

Note: All references are linked to online sources.

Updated: October 2, 2015
Clinical Outcomes—Paroxysmal

> 2 Year Follow-Up


< 2 Year Follow-Up

1. Podd SJ, Sulke AN, Sugihara C, Furniss SS. Phased multipolar radiofrequency pulmonary vein isolation is as effective and safe as conventional irrigated point-to-point ablation: A prospective randomised 1-year implantable cardiac monitoring device follow-up trial. J Interv Card Electrophysiol. Published online August 27, 2015.


Redos


Clinical Outcomes—Persistent

≤ 2 Year Follow-Up


**Acute Outcomes**


**Reviews and Meta-Analyses**


**Safety Focus**

**ACE**


Steinberg JS, Mittal S. Intracranial emboli associated with catheter ablation of atrial fibrillation: has the silence finally been broken? J Am Coll Cardiol. August 2011;9(5):689-691.


Anticoagulation


Esophageal Injury


Inflammation and Coagulation


Overall Complications


Phrenic Nerve Injury


PV Stenosis


Other Considerations

Predictors of Success


Linear Ablation


Imaging


Signal Quality


Voltage Mapping


Pre-Clinical and Technical


Case Studies


Guidelines and Consensus Statements


Brief Statement:

**PVAC™ GOLD Pulmonary Vein Ablation Catheter™ GOLD**

**Indications:** The Pulmonary Vein Ablation Catheter GOLD is designed to be used for the creation of endocardial lesions (focal and linear) during cardiac ablation procedures for the treatment of symptomatic Atrial Fibrillation (AF). The PVAC GOLD is also intended to be used for cardiac electrophysiological (EP) mapping of pulmonary vein potentials, delivery of diagnostic pacing stimuli and verifying electrical isolation of the pulmonary veins post-treatment.

**Contraindications:** Use of the Pulmonary Vein Ablation Catheter GOLD is contraindicated as follows:

- Active sepsis
- Left atrial thrombus or myxoma
- Atrial Septal Patch or atrial septal defect repair with percutaneous device
- Known sensitivity to heparin
- Blood clotting abnormalities
- Venous filtering device (Greenfield Filter)

The catheter is not recommended for use in patients who cannot undergo standard anticoagulation protocol for a left-sided cardiac procedure, or who have had a recent coagulopathy or embolic event.

**MAAC™ Multi-Array Ablation Catheter™**

**Indications:** The MAAC is indicated for the treatment of symptomatic, drug refractory, persistent atrial fibrillation (AF) or long-standing persistent AF of up to four years in duration. The MAAC is used for endocardial mapping, pacing, and ablating arrhythmogenic tissue in the left atrial body.

**Contraindications:** Use of the Multi-Array Ablation Catheter is contraindicated as follows:

- Active sepsis
- Left atrial thrombus or myxoma
- Atrial Septal Patch or atrial septal defect repair with percutaneous device
- Known sensitivity to heparin
- Blood clotting abnormalities
- Venous filtering device (Greenfield Filter)

The catheter is not recommended for use in patients who cannot undergo standard anticoagulation protocol for a left-sided cardiac procedure, or who have had a recent coagulopathy or embolic event.

**MASC™ Multi-Array Septal Catheter™**

**Indications:** The MASC is indicated for the treatment of symptomatic, drug refractory, persistent atrial fibrillation (AF) or long-standing persistent AF of up to four years in duration. The MASC is used for endocardial mapping, pacing, and ablating arrhythmogenic tissue in the left atrial body.

**Contraindications:** Use of the Multi-Array Septal Catheter is contraindicated as follows:

- Active sepsis
- Left atrial thrombus or myxoma
- Atrial Septal Patch or atrial septal defect repair with percutaneous device
- Known sensitivity to heparin
- Blood clotting abnormalities
- Venous filtering device (Greenfield Filter)

The catheter is not recommended for use in patients who cannot undergo standard anticoagulation protocol for a left-sided cardiac procedure, or who have had a recent coagulopathy or embolic event.

See the device manuals for detailed information regarding indications, contraindications, warnings, precautions, and potential adverse events.